Novo lost their patent protection for semaglutide in Canada because they failed to pay the maintenance fee. Oopsies.
Science.org | In the Pipeline | Novo Nordisk’s Canadian Mistake
1 Like
Wow, that’s crazy, thanks for posting.
I wonder if they didn’t care because of one of those manufacturing twists to effectively restart the patent timeline like what can happen with the analog insulins. Still, seems like a pretty big oversight